Jeffrey L. Cummings.
#68,993
Most Influential Person Across History
Jeffrey L. Cummings.'s AcademicInfluence.com Rankings
Download Badge
Medical Philosophy
Jeffrey L. Cummings.'s Degrees
- Doctorate Medicine University of Washington
- PhD Pharmacology University of Washington
Why Is Jeffrey L. Cummings. Influential?
(Suggest an Edit or Addition)Jeffrey L. Cummings.'s Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment (2005) (15368)
- The Neuropsychiatric Inventory (1994) (4737)
- Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007) (4004)
- Diagnosis and management of dementia with Lewy bodies (2005) (3346)
- Frontotemporal lobar degeneration (1998) (2750)
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
- Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) (2413)
- Frontal-subcortical circuits and human behavior. (1993) (1834)
- Revising the definition of Alzheimer's disease: a new lexicon (2010) (1793)
- Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
- Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. (2000) (1394)
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures (2014) (1385)
- The Neuropsychiatric Inventory (1997) (1365)
- Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) (1258)
- Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. (2002) (1205)
- Practice parameter: Diagnosis of dementia (an evidence-based review) (2001) (1178)
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
- Depression and Parkinson's disease: a review. (1992) (1072)
- The spectrum of behavioral changes in Alzheimer's disease (1996) (1053)
- Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. (2001) (863)
- Alzheimer's disease (2015) (796)
- Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. (2002) (748)
- Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. (2000) (734)
- Repurposed agents in the Alzheimer’s disease drug development pipeline (2020) (723)
- The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers (2006) (704)
- Frontal-subcortical circuits and neuropsychiatric disorders. (1994) (682)
- Dementia: A Clinical Approach (1983) (665)
- Apathy is not depression. (1998) (626)
- Alzheimer's disease and Parkinson's disease (1988) (589)
- The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery (2009) (588)
- Range of neuropsychiatric disturbances in patients with Parkinson’s disease (1999) (578)
- Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. (2000) (566)
- Subcortical dementia. Review of an emerging concept. (1984) (561)
- Assessing the Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: The Neuropsychiatric Inventory Caregiver Distress Scale (1998) (552)
- Frontal-subcortical circuits and human behavior. (1998) (530)
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial (2014) (506)
- Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. (2006) (502)
- Frontal-subcortical circuitry and behavior (2007) (497)
- A potential role of the curry spice curcumin in Alzheimer's disease. (2005) (495)
- Huntington's disease. (1997) (492)
- Alzheimer's disease drug development pipeline: 2019 (2019) (491)
- Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
- Alzheimer's disease drug development pipeline: 2018 (2018) (474)
- Neuropsychiatric aspects of Huntington's disease (2001) (469)
- Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress (2006) (448)
- The occurrence of depression in Parkinson's disease. A community-based study. (1996) (447)
- Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. (2001) (445)
- Alzheimer's disease (1998) (425)
- Depression in epilepsy. Significance and phenomenology. (1986) (423)
- Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease (2018) (411)
- The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. (2000) (394)
- White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. (2003) (389)
- Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. (1987) (383)
- Emergence of artistic talent in frontotemporal dementia (1998) (382)
- Provisional diagnostic criteria for depression of Alzheimer disease. (2002) (381)
- Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study (2012) (381)
- The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. (1983) (379)
- Anatomic and Behavioral Aspects of Frontal‐Subcortical Circuits a (1995) (374)
- Cholinesterase inhibitors: A new class of psychotropic compounds. (2000) (370)
- Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease (2004) (370)
- The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. (2000) (354)
- A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting (2001) (349)
- Management of agitation and aggression associated with Alzheimer disease (2009) (347)
- Neuropsychiatric Manifestations in Mild Cognitive Impairment: A Systematic Review of the Literature (2007) (340)
- The temporal variant of frontotemporal dementia. (1997) (338)
- Management of behavioral problems in Alzheimer's disease (2010) (338)
- PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. (2010) (333)
- Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease (2019) (330)
- Current state of Alzheimer’s fluid biomarkers (2018) (327)
- Aphasia in dementia of the Alzheimer type (1985) (323)
- Alzheimer's disease drug development pipeline: 2017 (2017) (320)
- Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group (2006) (316)
- Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology (2007) (314)
- Executive dysfunction and apathy predict functional impairment in Alzheimer disease. (2003) (311)
- Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study (2007) (304)
- Drug development in Alzheimer’s disease: the path to 2025 (2016) (295)
- Subcortical Dementia Neuropsychology, Neuropsychiatry, and Pathophysiology (1986) (292)
- Frequency of dementia in Parkinson disease. (1996) (291)
- Cortical variability and asymmetry in normal aging and Alzheimer's disease. (1998) (280)
- A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule (2007) (277)
- Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease (2001) (275)
- Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
- Alzheimer disease and frontotemporal dementias. Behavioral distinctions. (1996) (272)
- On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (269)
- A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. (2003) (269)
- Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia (2000) (268)
- The limbic system: an anatomic, phylogenetic, and clinical perspective. (1997) (267)
- Neuropsychiatric symptoms and quality of life in Alzheimer disease. (2005) (265)
- The neuroanatomy of depression. (1993) (265)
- Disease-modifying therapies for Alzheimer disease (2007) (264)
- Executive Control Function (2002) (263)
- Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors (1997) (261)
- Organic Delusions: Phenomenology, Anatomical Correlations, and Review (1985) (260)
- Behavioral Syndromes in Alzheimer’s Disease: Description and Correlates (1999) (257)
- Frontal lobe degeneration (1991) (257)
- The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. (1998) (253)
- 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. (2006) (253)
- Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. (1996) (247)
- Mild Cognitive Impairment is Associated With Characteristic Neuropsychiatric Symptoms (2004) (246)
- Prevalence and impact of medical comorbidity in Alzheimer's disease. (2002) (243)
- Obsessions and compulsions in Gilles de la Tourette's syndrome (1986) (235)
- Neuropsychiatric aspects of progressive supranuclear palsy (1996) (232)
- Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. (2008) (231)
- Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options (2019) (230)
- The human Klüver‐Bucy syndrome (1983) (229)
- Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition (2014) (228)
- The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. (1999) (228)
- Serotonin 1A receptors in the living brain of Alzheimer's disease patients. (2006) (227)
- Cognitive Function in Non‐Demented Older Adults with Hypothyroidism (1992) (226)
- Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. (2007) (226)
- Secondary mania with focal cerebrovascular lesions. (1984) (224)
- Cerebral blood flow correlates of apathy in Alzheimer disease. (1996) (223)
- MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. (1999) (221)
- A study of the Lund‐Manchester research criteria for frontotemporal dementia (1997) (219)
- The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. (2017) (219)
- Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurobiological basis (2000) (217)
- In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. (2000) (216)
- Amnesia with hippocampal lesions cardiopulmonary arrest (1984) (213)
- Mild cognitive impairment (2005) (213)
- Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study (1996) (212)
- Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment (2006) (212)
- Are Unilateral Right Posterior Cerebral Lesions Sufficient to Cause Prosopagnosia? Clinical and Radiological Findings in Six Additional Patients (1986) (210)
- Neuropsychiatric manifestations of multiple sclerosis. (1999) (208)
- Effective pharmacologic management of Alzheimer's disease. (2007) (207)
- Functional correlates of musical and visual ability in frontotemporal dementia (2000) (205)
- Behavioural changes and psychological symptoms in dementia disorders (2005) (204)
- Depression in patients with Parkinson's disease (1999) (204)
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group (2021) (204)
- Biochemical markers in persons with preclinical familial Alzheimer disease (2008) (204)
- Loss of topographic familiarity. An environmental agnosia. (1986) (201)
- Quetiapine for agitation or psychosis in patients with dementia and parkinsonism (2007) (200)
- Hypersexuality or altered sexual preference following brain injury. (1986) (199)
- Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates (1988) (198)
- The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia (2010) (198)
- Neuropsychiatric aspects of Alzheimer's disease (1996) (198)
- Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia (1997) (197)
- A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. (1993) (197)
- Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes (2017) (197)
- Vascular subcortical dementias: clinical aspects. (1994) (194)
- Risk factors for depression in Parkinson disease. (1997) (192)
- The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. (1995) (191)
- The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. (2011) (190)
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody (2020) (190)
- Positron emission tomography metabolic correlates of apathy in Alzheimer disease. (2007) (189)
- Increased basal ganglia iron levels in Huntington disease. (1999) (184)
- Neuropsychiatric Symptoms Are Associated with Progression from Mild Cognitive Impairment to Alzheimer’s Disease (2007) (183)
- Frontal-subcortical circuits in psychiatric and neurological disorders (2001) (181)
- Cerebral correlates of psychotic symptoms in Alzheimer's disease (2000) (181)
- Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. (2003) (179)
- Neuropsychiatric symptoms in the dementias (2002) (178)
- Guidelines for managing Alzheimer's disease: Part II. Treatment. (2002) (176)
- Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. (2011) (175)
- A quantitative MRI study of vascular dementia (1992) (175)
- Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. (2003) (173)
- Expletives: neurolinguistic and neurobehavioral perspectives on swearing (1999) (173)
- Executive dysfunction in Alzheimer disease. (2004) (171)
- Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD (2002) (170)
- Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. (2006) (170)
- Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. (1996) (169)
- Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. (2004) (168)
- Metrifonate treatment of the cognitive deficits of Alzheimer's disease (1998) (167)
- Structural Correlates of Apathy in Alzheimer’s Disease (2007) (166)
- Dementia with Lewy bodies (1996) (165)
- Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect (2010) (164)
- Voice perception deficits: neuroanatomical correlates of phonagnosia. (1989) (164)
- Behavioral Complications of Drug Treatment of Parkinson's Disease (1991) (163)
- Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. (2000) (161)
- Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. (2003) (161)
- Apathy and executive function in Alzheimer's disease (2002) (158)
- Phonagnosia: A Dissociation Between Familiar and Unfamiliar Voices (1988) (156)
- Obsessive-compulsive disorder in Huntington's disease (1992) (155)
- Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. (1997) (154)
- Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia (1996) (154)
- Kluver‐Bucy Syndrome in Pick disease (1981) (153)
- Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. (2015) (151)
- Personality alterations in dementia of the Alzheimer type. (1988) (148)
- Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia (2010) (147)
- Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. (2000) (145)
- Neuropathologic Correlates of Apathy in Alzheimer’s Disease (2006) (144)
- The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease (2003) (143)
- Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease (2001) (142)
- Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. (2006) (142)
- Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease (2010) (141)
- Defining and Diagnosing Involuntary Emotional Expression Disorder (2006) (141)
- Neuropsychiatric features of corticobasal degeneration (1998) (140)
- The Human Frontal Lobes: Functions and Disorders (2013) (138)
- Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. (2005) (138)
- Donepezil delays progression to AD in MCI subjects with depressive symptoms (2009) (137)
- Disease-modifying therapies in Alzheimer’s disease ⁎ ⁎ EDITOR’S NOTE: The Journal intended to include this article in the January 2008 supplement, “Leon Thal Symposium on Prevention of Dementia.” (2008) (137)
- Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. (2004) (137)
- Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. (1995) (135)
- Chronic divalproex sodium use and brain atrophy in Alzheimer disease (2011) (132)
- Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions (2015) (131)
- Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. (2009) (129)
- Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment. (1998) (129)
- Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. (2007) (127)
- Evaluating dementia screening tests (1999) (127)
- The pattern of reading deterioration in dementia of the Alzheimer type: Observations and implications (1986) (127)
- Assessment of Cognitive, Psychiatric, and Behavioral Disturbances in Patients with Dementia: The Neurobehavioral Rating Scale (1992) (127)
- 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
- Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. (2006) (125)
- Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. (1998) (124)
- Cordance: A New Method for Assessment of Cerebral Perfusion and Metabolism Using Quantitative Electroencephalography (1994) (124)
- The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities (1995) (123)
- Physostigmine ameliorates the delusions of Alzheimer's disease (1993) (123)
- Behavioral and psychiatric symptoms associated with Huntington's disease. (1995) (123)
- Vascular dementia and dementia of the Alzheimer type. Cognition, ventricular size, and leuko-araiosis. (1988) (123)
- Repetitive and compulsive behavior in frontal lobe degenerations. (1994) (122)
- Behavioral Disorders and Caregivers' Reaction in Taiwanese Patients With Alzheimer's Disease (2001) (122)
- Dementia and neurodevelopmental predisposition: Cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia (2001) (121)
- Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies (2002) (121)
- Noncognitive neuropsychiatric syndromes in alzheimer’s disease (1990) (120)
- The “rights” of precision drug development for Alzheimer’s disease (2019) (120)
- Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. (2012) (120)
- Neuropsychiatric Symptoms and Cholinergic Therapy for Alzheimer’s Disease (1999) (119)
- Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. (1983) (119)
- Alzheimer's disease drug development pipeline: 2020 (2020) (118)
- Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. (1998) (117)
- Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease (2016) (117)
- Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction (2003) (116)
- Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases (2005) (116)
- Validation study of the Chinese version of the neuropsychiatric inventory (CNPI) (2001) (116)
- Angular gyrus syndrome simulating Alzheimer's disease. (1982) (114)
- Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. (2001) (113)
- Behavioral disorders in Alzheimer disease: a transcultural perspective. (1998) (113)
- Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials (2018) (111)
- Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease (2003) (110)
- Comorbidity in dementia: an autopsy study. (2004) (107)
- Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study (2018) (107)
- The Alzheimer ’ s Disease Centers ’ Uniform Data Set ( UDS ) : The Neuropsychological Test Battery (2009) (107)
- Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. (1991) (104)
- Behavioral effects of current Alzheimer’s disease treatments: A descriptive review (2008) (104)
- Relational integration and executive function in Alzheimer's disease. (2004) (103)
- Gilles de la Tourette syndrome and the neurological basis of obsessions and compulsions (1985) (102)
- Mini-Mental State Examination. Norms, normals, and numbers. (1993) (102)
- Depressive Symptoms in Alzheimer Disease: Assessment and Determinants (1995) (101)
- Early-Onset Alzheimer’s Disease Is Associated With Greater Pathologic Burden (2007) (101)
- First Symptoms – Frontotemporal Dementia versus Alzheimer’s Disease (2000) (100)
- Current therapeutic targets for the treatment of Alzheimer’s disease (2010) (99)
- Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia (2005) (99)
- Senile Dementia of the Alzheimer Type (1987) (99)
- Guidelines for managing Alzheimer's disease: part I. Assessment. (2002) (98)
- Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease (2019) (98)
- Dementia of the Alzheimer Type (1986) (98)
- Amnesia with hippocampal lesions after cardiopulmonary arrest. (1996) (97)
- ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease (2018) (97)
- Association of GSK3B with Alzheimer disease and frontotemporal dementia. (2008) (96)
- Frontotemporal dementia versus Alzheimer's disease (1996) (94)
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials (2016) (94)
- Treatment of Alzheimer's disease: current and future therapeutic approaches. (2004) (94)
- Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. (2005) (93)
- Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future1 (2018) (92)
- Neuropsychiatric assessment of Alzheimer’s disease and related dementias (2001) (91)
- Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. (2008) (90)
- Midlatency auditory evoked responses: differential abnormality of P1 in Alzheimer's disease. (1989) (90)
- Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies (2016) (88)
- Encephalitis lethargica: lessons for contemporary neuropsychiatry. (1995) (88)
- Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. (2005) (88)
- The “yips” (1989) (87)
- Subtle Deficits in Instrumental Activities of Daily Living in Subtypes of Mild Cognitive Impairment (2010) (87)
- Mutism: review, differential diagnosis, and report of 22 cases. (1986) (87)
- 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI (2010) (87)
- Neuropsychiatric Manifestations of Right Hemisphere Lesions (1997) (85)
- Biomarkers in Alzheimer's disease drug development (2011) (85)
- Alzheimer's disease (2021) (85)
- Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. (2000) (84)
- Toward a molecular neuropsychiatry of neurodegenerative diseases (2003) (84)
- Developing the ATX(N) classification for use across the Alzheimer disease continuum (2021) (83)
- Alzheimer's drug-development pipeline: 2016 (2016) (82)
- Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects (2010) (82)
- A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents (2013) (81)
- Brain Ferritin Iron as a Risk Factor for Age at Onset in Neurodegenerative Diseases (2004) (81)
- Depression in Parkinson’s Disease (1998) (80)
- Parkinson's Disease: Neurobehavioral Aspects (1992) (80)
- Organic psychoses. Delusional disorders and secondary mania. (1986) (80)
- Screening for dementia: comparison of three commonly used instruments. (1999) (79)
- Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer’s Disease (2012) (78)
- Hypersexuality following septal injury. (1992) (78)
- Dysprosodic speech following basal ganglia insult: Toward a conceptual framework for the study of the cerebral representation of prosody (2006) (78)
- The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials (2018) (77)
- The cognitive syndrome of vascular dementia: implications for clinical trials. (1999) (77)
- Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. (2012) (76)
- Sensitivity, Specificity, and Positive Predictive Value of Technetium 99-HMPAO SPECT in Discriminating Alzheimer's Disease from other Dementias (1997) (76)
- Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. (2012) (75)
- Precision pharmacology for Alzheimer's disease. (2018) (74)
- New approaches to symptomatic treatments for Alzheimer’s disease (2021) (74)
- Compulsive Behaviors as Presenting Symptoms of Frontotemporal Dementia (1997) (74)
- Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. (1996) (74)
- Probable Alzheimer's disease in an artist. (1987) (73)
- The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. (2000) (73)
- International Work Group criteria for the diagnosis of Alzheimer disease. (2013) (72)
- Idiopathic basal ganglia calcification and organic mood disorder. (1988) (72)
- The neuropsychiatry of limbic and subcortical disorders (1997) (72)
- Left‐to‐right transfer of language dominance (1979) (72)
- What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease? (2010) (71)
- Defining Disease Modifying Therapy for Alzheimer's Disease. (2017) (71)
- Personality Alterations in Dementia of the Alzheimer Type: A Three-Year Follow-up Study (1989) (70)
- 3D mapping of language networks in clinical and pre-clinical Alzheimer’s disease (2008) (70)
- Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. (2015) (70)
- Neuropsychiatric symptoms from the temporolimbic lobes. (1997) (70)
- Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease (1999) (69)
- A practical algorithm for managing Alzheimer's disease: what, when, and why? (2015) (69)
- Montreal Cognitive Assessment (2014) (69)
- Current and Emerging Pharmacological Treatment Options for Dementia (2006) (68)
- Visual hallucinations. Clinical occurrence and use in differential diagnosis. (1987) (68)
- Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications (2013) (68)
- Quantitative EEG in Frontotemporal Dementia (1996) (67)
- Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. (1998) (67)
- Pharmacokinetic rationale for the rivastigmine patch (2007) (66)
- Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI) (2004) (66)
- Toward a more precise, clinically—informed pathophysiology of pathological laughing and crying (2013) (66)
- Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. (2014) (65)
- The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995. (1999) (65)
- 3D Mapping of Mini-mental State Examination Performance in Clinical and Preclinical Alzheimer Disease (2006) (65)
- The neuropsychiatry of Alzheimer's disease and other dementias (2003) (64)
- ADCS Prevention Instrument Project: Overview and Initial Results (2006) (64)
- Risk Factors for Behavioral Abnormalities in Mild Cognitive Impairment and Mild Alzheimer's Disease (2014) (64)
- Speech and language alterations in multi‐infarct dementia (1988) (64)
- The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. (2014) (63)
- Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. (2013) (63)
- Psychosis in neurologic disease : neurobiology and pathogenesis : Psychosis in neurologic diseases (1992) (63)
- Bilingualism and dementia. (1999) (62)
- Positron emission computed tomography in the diagnosis of dementia. (1981) (62)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021) (62)
- Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology (2011) (62)
- Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development (2013) (62)
- Positron Emission Tomography in Evaluation of Dementia (2001) (62)
- Defining and labeling disease-modifying treatments for Alzheimer's disease (2009) (61)
- Drug repositioning and repurposing for Alzheimer disease (2020) (61)
- Speech and language in progressive nonfluent aphasia compared with early Alzheimer’s disease (2003) (61)
- Late-life paraphrenia: an organic delusional syndrome. (1986) (60)
- Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. (2003) (60)
- Behavior and mood disorders in focal brain lesions (2000) (60)
- Reversible dementia. Illustrative cases, definition, and review. (1980) (60)
- The Role of Biomarkers in Alzheimer's Disease Drug Development. (2019) (60)
- The A431E mutation in PSEN1 causing Familial Alzheimer’s Disease originating in Jalisco State, Mexico: an additional fifteen families (2006) (60)
- Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. (2001) (60)
- Incidence of dementia and subtypes: A cohort study in four regions in China (2016) (60)
- Deficits in Facial Emotion Processing in Mild Cognitive Impairment (2007) (59)
- Concordance of the Montreal cognitive assessment with standard neuropsychological measures (2015) (58)
- Behavioral Differences Between Frontotemporal Dementia and Alzheimer's Disease: A Comparison on the BEHAVE-AD Rating Scale (1998) (58)
- Relative tolerability of Alzheimer's disease treatments. (2008) (57)
- The price of progress: Funding and financing Alzheimer's disease drug development (2018) (57)
- Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease (2001) (57)
- Discovering new treatments for Alzheimer's disease by repurposing approved medications. (2013) (57)
- Effects of ApoE4 and maternal history of dementia on hippocampal atrophy (2012) (56)
- The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. (2000) (56)
- The Exceptional Brain: Neuropsychology of Talent and Special Abilities (1989) (56)
- Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. (2007) (55)
- High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines (2013) (54)
- Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers (1999) (54)
- Confabulation in Alzheimer's disease (1992) (54)
- Neuropathologic Correlates of Activities of Daily Living in Alzheimer Disease (2006) (54)
- Practicality of a computerized system for cognitive assessment in the elderly (2008) (53)
- Sulcal variability in the Alzheimer's brain (1998) (53)
- Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. (2003) (53)
- Dementia and depression: an evolving enigma. (1989) (51)
- Alzheimer disease. (2002) (51)
- A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
- Disease modification and Neuroprotection in neurodegenerative disorders (2017) (50)
- Frontal-Subcortical Dementias (2008) (50)
- Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. (2016) (50)
- Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease (2011) (49)
- Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative (2013) (49)
- Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. (2012) (49)
- The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier) (2013) (49)
- Subcortical disease and neuropsychiatric illness. (1994) (49)
- Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. (2002) (48)
- Gender-Related Cognitive Deficits in Alzheimer's Disease (1999) (48)
- Integrating ADNI results into Alzheimer's disease drug development programs 1 1 Prepared for a special issue of Neurobiology of Aging on the Alzheimer's Disease Neuroimaging Initiative (ADNI). (2010) (48)
- Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials (2006) (48)
- Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease (2012) (48)
- The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments (2013) (48)
- A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson’s Disease versus Alzheimer’s Disease (2008) (48)
- Alzheimer Disease and the Dementia of Parkinson Disease: Comparative Investigations (1990) (48)
- Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease (2009) (47)
- Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease (1997) (47)
- Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's Disease (2005) (46)
- A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia (2007) (46)
- Contemporary behavioral neurology (1997) (46)
- Frontal subcortical circuits: anatomy and function (2001) (46)
- Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. (1998) (45)
- The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. (1988) (45)
- Alzheimer's disease and related disorders annual (2000) (45)
- Alzheimer's disease and its management in the year 2010. (1999) (45)
- Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease (2015) (45)
- Possible association of the tau H1/H1 genotype with primary progressive aphasia (2003) (44)
- Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force (2019) (44)
- Neuropsychiatric Disturbances following Brainstem Lesions (1981) (44)
- Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review (2003) (44)
- The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline (2014) (44)
- Pimavanserin: Potential Treatment For Dementia-Related Psychosis (2018) (44)
- Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. (1999) (44)
- Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers (2018) (43)
- Appropriateness of Quality Indicators for Older Patients with Advanced Dementia and Poor Prognosis (2003) (43)
- Clinical trials in predementia stages of Alzheimer disease. (2013) (43)
- Neuro‐opthalmic abnormalities in Tourette's syndrome (1984) (43)
- Psychological dysfunction accompanying subcortical dementias. (1988) (43)
- Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. (2002) (42)
- Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. (1997) (42)
- Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. (2019) (42)
- Overcoming obstacles to repurposing for neurodegenerative disease (2014) (42)
- The Neuropsychiatric Inventory: Development and Applications (2020) (42)
- Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies (2006) (42)
- Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial (2000) (41)
- Functional Ability in Executive Variant Alzheimer's Disease and Typical Alzheimer's Disease (2002) (41)
- Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease (2012) (41)
- Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. (2016) (41)
- Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. (2013) (40)
- A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). (2015) (40)
- Metrifonate: update on a new antidementia agent. (1999) (40)
- Predicting cognitive decline in Alzheimer's disease: An integrated analysis (2010) (40)
- Cholinergic therapy of behavioral disturbances in Alzheimer's disease (1993) (40)
- Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification (2004) (39)
- Central dazzle. A thalamic syndrome? (1981) (39)
- Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based (2004) (38)
- Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing (2020) (38)
- Alzheimer's disease diagnostic criteria: practical applications (2012) (38)
- Reversible Dementia: Illustrative Cases, Definition, and Review (1980) (38)
- Dementia: the failing brain (1995) (38)
- Cholinesterase inhibitors: expanding applications (2000) (38)
- Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease (2016) (38)
- Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease (2019) (38)
- Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases (2019) (38)
- ABBY (2018) (38)
- Sneddon's Syndrome Is a Thrombotic Vasculopathy (1995) (37)
- The Future of Anti-Amyloid Trials (2019) (37)
- Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume (2017) (37)
- Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. (2019) (36)
- Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response (2013) (36)
- A real reason for patients with pseudobulbar affect to smile (2007) (36)
- Neuropsychiatric Aspects of Stroke (1991) (36)
- Definitions and diagnostic criteria (2006) (36)
- Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. (2017) (36)
- Parkinson's disease, depression, and the on-off phenomenon. (1989) (36)
- Advances in designs for Alzheimer's disease clinical trials. (2012) (35)
- A counseling intervention for caregivers: effect on neuropsychiatric symptoms (2004) (35)
- Neuropsychiatric and Behavioral Symptoms in a Community Sample of Hispanics With Alzheimer's Disease (2006) (35)
- Apathy in Neurodegenerative Diseases (2015) (35)
- Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. (2005) (35)
- Persistence of Neuropsychological Testing Deficits in Mild Cognitive Impairment (2009) (35)
- Understanding Parkinson disease. (1999) (35)
- Managing psychosis in patients with Parkinson's disease. (1999) (35)
- Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease (2018) (34)
- Frontotemporal Dementia Classification and Neuropsychiatry (2002) (34)
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis (2021) (34)
- Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study (2016) (34)
- Depression in vascular dementia. (1988) (34)
- Trial of Pimavanserin in Dementia-Related Psychosis. (2021) (33)
- Drug-Induced Mania - Causative Agents,Clinical Characteristics and Management (1989) (33)
- Assessment of cerebral perfusion using quantitative EEG cordance (1994) (33)
- Behavioral and Neuropsychiatric Outcomes in Alzheimer's Disease (2005) (33)
- Cortical and Hippocampal Atrophy in Patients with Autosomal Dominant Familial Alzheimer’s Disease (2011) (33)
- Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease (2019) (33)
- Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease (2010) (33)
- Effects of Anticholinergic Agents on Patients with Tardive Dyskinesia and Concomitant Drug‐Induced Parkinsonism (1989) (33)
- Neuropsychiatric aspects of corticobasal degeneration. (2000) (33)
- Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. (1994) (32)
- Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease (2007) (32)
- Abnormal erythrocyte choline and influx in Alzheimer's disease. (1986) (32)
- Mutism: loss of neocortical and limbic vocalization. (1983) (32)
- Globalization of Alzheimer's disease clinical trials (2011) (32)
- Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease. (2008) (31)
- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. (2020) (31)
- Autistic savants. [correction of artistic]. (2000) (31)
- Speech and language alterations in dementia syndromes: Characteristics and treatment (1990) (31)
- Health-related quality-of-life and service utilization in Alzheimer's disease: A cross-sectional study (2000) (31)
- Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect". (2016) (30)
- Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. (2019) (30)
- Neurobehavioral Consequences of Neurosurgical Treatments and Focal Lesions of Frontal-Subcortical Circuits (2009) (30)
- Organic psychosis. (1988) (30)
- Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. (2011) (30)
- Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease (2018) (29)
- Optimizing phase II of drug development for disease-modifying compounds (2008) (29)
- Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. (2020) (29)
- De Clérambault's Syndrome in Organic Affective Disorder (1987) (29)
- Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. (2010) (29)
- Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels (2014) (28)
- Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease (2008) (28)
- A New Measurement of Activities of Daily Living for Thai Elderly With Dementia (2003) (28)
- Treatment of Alzheimers' disease (2001) (28)
- CME Practice parameter : Early detection of dementia : Mild cognitive impairment ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) (28)
- Behavioral neurology of multi-infarct dementia. (1991) (28)
- Altered behavior associated with damage to the ventromedial hypothalamus: a distinctive syndrome. (1988) (28)
- The American Psychiatric Press Textbook of Geriatric Neuropsychiatry (2000) (28)
- Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease (2020) (28)
- AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery (2021) (27)
- Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. (1990) (27)
- Psychometric and SPECT studies in alzheimer’s disease with and without delusions (1995) (27)
- Alzheimer’s disease progression by geographical region in a clinical trial setting (2015) (27)
- Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer’s Disease (2018) (27)
- Neuropsychiatric aspects of dementia with lewy bodies (1999) (27)
- Theories Behind Existing Scales for Rating Behavior in Dementia (1997) (27)
- Psychosomatic aspects of movement disorders. (1985) (27)
- Advances in the treatment of behavioral disturbances in Alzheimer’s disease (1999) (26)
- Multi-infarct dementia: diagnosis and management. Infarctions produce 20% to 35% of severe dementia cases. (1987) (26)
- Controversies in Alzheimer's disease drug development (2008) (26)
- Higher Working Memory Predicts Slower Functional Decline in Autopsy-Confirmed Alzheimer's Disease (2014) (26)
- Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. (2009) (26)
- Clinical drug development for dementia with Lewy bodies: past and present (2019) (25)
- A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease (2003) (25)
- The human frontal lobes: Functions and disorders, 2nd ed. (2007) (25)
- Metrifonate: Overview of Safety and Efficacy (1998) (25)
- Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics (2015) (25)
- Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019” (2020) (25)
- Monosymptomatic Delusions of Parasitosis Associated With Ischemic Cerebrovascular Disease (1989) (25)
- Frontal/Subcortical Features of Normal Aging: An Empirical Analysis (1990) (25)
- Dementia with Leukoaraiosis: Clinical Differentiation by Temporoparietal Hypometabolism on 18FDG-PET Imaging (1999) (24)
- Alzheimer's disease drug development: translational neuroscience strategies (2013) (24)
- Neuropsychiatric Inventory-Nursing Home Version (NPI-NH): validación española (2005) (24)
- Benefit-Risk Considerations in the Treatment of Dementia with Lewy Bodies (2002) (24)
- Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer’s Disease (2019) (24)
- Frontotemporal Dementia Versus Vascular Dementia: Differential Features on Mental Status Examination (1997) (24)
- P4-344: Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: Tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study (2008) (24)
- Repackaging FDA-approved drugs for degenerative diseases: promises and challenges (2014) (24)
- Principles of behavioral and cognitive neurology, 2nd edition (2001) (24)
- Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia (2015) (24)
- Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer’s Disease (2012) (23)
- Plasma Methionine Sulfoxide in Persons with Familial Alzheimer’s Disease Mutations (2012) (23)
- Delusions Induced by Procaine Penicillin: Case Report and Review of the Syndrome (1987) (23)
- Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY) (2018) (23)
- Posterior cortical atrophy: Unique features. (1998) (23)
- A videotape-based training method for improving the detection of depression in residents of long-term care facilities. (2002) (23)
- Reviewing the role of donepezil in the treatment of Alzheimer's disease. (2012) (22)
- Personality alterations in multi-infarct dementia. (1990) (22)
- Electromechanical characteristics of tardive dyskinesia. (1991) (22)
- Neurology, psychiatry, and neuropsychiatry (1994) (22)
- Increased fMRI signal with age in familial Alzheimer's disease mutation carriers (2012) (22)
- Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. (1999) (22)
- Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. (2007) (22)
- Guidelines for Managing Alzheimer's Disease (2002) (22)
- The insistent call from functional MRI (1997) (22)
- Recent developments in neurobiology of obsessive-compulsive disorder. (1996) (22)
- Effects of Oral Rivastigmine on Cognitive Domains in Mild-to-Moderate Alzheimer’s Disease (2010) (22)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE (2014) (22)
- Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
- Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials (2015) (21)
- The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. (2020) (21)
- The one-minute mental status examination (2004) (21)
- The dementia and disability project in Thai elderly: rational, design, methodology and early results (2013) (21)
- Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study (2013) (21)
- The Human Frontal Lobes Second Edition: Functions and Disorders (2007) (20)
- The ADCS valproate neuroprotection trial: Primary efficacy and safety results (2009) (20)
- Quantitative electroencephalographic correlates of psychosis in Alzheimer disease. (2000) (20)
- Normal aging and the subcortical encephalopathy of aids a neuropsychological comparison (1989) (20)
- Neuro-ophthalmic abnormalities in Tourette's syndrome: functional and anatomic implications. (1984) (20)
- Altered sexual behavior with multiple sclerosis: a case report (1993) (20)
- Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials (2020) (20)
- Rivastigmine Transdermal Patch Skin Tolerability (2010) (20)
- Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. (2014) (20)
- Increased Prevalence of Significant Recurrent Headache in Preclinical Familial Alzheimer’s Disease Mutation Carriers (2008) (19)
- What we can learn from open-label extensions of randomized clinical trials. (2006) (19)
- Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease (2016) (19)
- Organic personality disorder in dementia syndromes: an inventory approach. (1990) (19)
- Recognition and Differential Diagnosis of Tardive Dyskinesia (1990) (19)
- Surface Feature-Guided Mapping of Cerebral Metabolic Changes in Cognitively Normal and Mildly Impaired Elderly (2009) (19)
- Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia (2010) (19)
- Behavioral and emotional changes after focal frontal lobe damage (2000) (19)
- Klüver‐Bucy syndrome in Pick's disease (1983) (19)
- Fluctuations in cognitive function in dementia with Lewy bodies (2004) (19)
- Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. (1999) (19)
- Neuropsychiatric inventory workshop: behavioral and psychologic symptoms of dementia in Asia. (2006) (19)
- Alzheimer's disease biomarkers: Correspondence between human studies and animal models (2013) (19)
- Alzheimer's disease biomarkers in animal models: closing the translational gap. (2013) (19)
- Biomarker‐Driven Therapeutic Management of Alzheimer's Disease: Establishing the Foundations (2013) (18)
- Involuntary Emotional Expression Disorder: Definition, Diagnosis, and Measurement Scales (2007) (18)
- Alzheimer's disease: from molecular biology to neuropsychiatry. (2003) (18)
- Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force. (2015) (18)
- 9 – Brain Mapping in Dementia (2000) (18)
- Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch (2015) (18)
- [Neuropsychiatric Inventory-Nursing Home version (NPI-NH): Spanish validation]. (2005) (18)
- Unique white matter structural connectivity in early-stage drug-naive Parkinson disease (2019) (18)
- Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes (2014) (18)
- The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview (2020) (18)
- Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors (2000) (18)
- Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials (2015) (17)
- Statistical advances in clinical trials and clinical research (2018) (17)
- Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. (2018) (17)
- Palinopsia reconsidered (1982) (17)
- Postpoliomyelitis syndrome: Assessment of behavioral features (1989) (17)
- Regression to the mean: implications for clinical trials of psychotropic agents in dementia. (2004) (17)
- Concise Guide to Neuropsychiatry and Behavioral Neurology (1995) (17)
- Temporal lobe epilepsy: its association with psychiatric impairment and appropriate dental management. (1989) (16)
- Tardive dyskinesia in schizophrenic patients: Correlation with negative symptoms (1989) (16)
- Dental treatment of patients with Gilles de la Tourette's syndrome. (1992) (16)
- Apolipoprotein ϵ4 status is associated with behavioral symptoms in nursing home residents with dementia (2009) (16)
- Amyloid-based interventions in Alzheimer's disease (2007) (16)
- A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages (2020) (16)
- Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease (2019) (16)
- Organic delusional syndrome. (1990) (16)
- Non-Inferiority Trials (2012) (16)
- Depression in Neurologic Diseases (1994) (16)
- The Black Book of Alzheimer's Disease, Part 1 (2008) (16)
- Driving health IT implementation success: Insights from The Christ Hospital (2010) (16)
- Delusions and mood disorders in patients with chronic aphasia. (1989) (16)
- Alzheimer’s Disease Clinical Trials: Changing the Paradigm (2011) (16)
- A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms (2019) (16)
- Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease (2013) (16)
- Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD (2019) (16)
- Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease (2015) (16)
- Souvenaid in the management of mild cognitive impairment: an expert consensus opinion (2019) (16)
- Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study (2018) (16)
- Treatable dementias. (1983) (16)
- Neurobehavioural examination of frontal lobe functions (1995) (16)
- Neuropsychiatry, neuropsychology, and behavioral neurology : a critical comparison (1995) (15)
- Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity (2013) (15)
- Disorders of motivation (2000) (15)
- Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease (2005) (15)
- Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume (2018) (15)
- Single Photon Emission Computed Tomography in Dementia: Relationship of Perfusion to Cognitive Deficits (1993) (15)
- Has the management of Alzheimer's disease changed over the past 100 years? (2006) (15)
- Clinical evaluation as a biomarker for Alzheimer's disease. (2006) (15)
- Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease (2005) (15)
- Positron-emission tomography in tardive dyskinesia. (1995) (15)
- Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. (2010) (15)
- Epilepsy: psychiatric aspects and use of psychotropics. (1984) (14)
- Dextromethorphan/Quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons With Alzheimer’s Disease: Results From a Phase 2 Study (NCT01584440) (S16.007) (2015) (14)
- A probabilistic atlas of the human brain in alzheimer's disease: Emerging patterns of variability, asymmetry and degeneration (1999) (14)
- Drug therapy in Alzheimer's disease [5] (multiple letters) (2004) (14)
- Treatment of Alzheimer's disease. (2001) (14)
- Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. (2016) (14)
- Mood and behavior in disorders of the basal ganglia (2000) (14)
- Comparison of electromechanical measures and observer ratings of tardive dyskinesia (1989) (14)
- Cholinesterase inhibitors in non-Alzheimer dementias. (2003) (14)
- Subcortical Structures and Neuropsychiatric Illness (1996) (14)
- Spanish Instrument Protocol: New Treatment Efficacy Instruments for Spanish-speaking Patients in Alzheimer Disease Clinical Trials (2006) (14)
- Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020) (2013) (14)
- The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico. (2002) (14)
- A Transcultural Study of Agitation in Dementia (2002) (14)
- Association of GSK 3 B With Alzheimer Disease and Frontotemporal Dementia (2008) (14)
- Sex Moderates Amyloid and Apolipoprotein ε4 Effects on Default Mode Network Connectivity at Rest (2019) (14)
- Comorbidity in Dementia (2009) (14)
- The utility of the new research diagnostic criteria for Alzheimer's disease (2012) (14)
- Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program (2018) (13)
- Neurobehavioral presentations of the antiphospholipid antibody syndrome. (1993) (13)
- The American Psychiatric Publishing Textbook of Geriatric Neuropsychiatry (2011) (13)
- Alzheimer's disease : treatment and long-term management (1990) (13)
- Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. (2020) (13)
- Cognitive and Noncognitive Aspects of Dementia Syndromes: An Overview (1994) (13)
- Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis (2008) (13)
- Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume (2019) (13)
- Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force (2018) (13)
- Independent contributions of neural and “higher-order” deficits to symptoms in Alzheimer’s disease: A latent variable modeling approach (2006) (13)
- Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia (2021) (13)
- Autism Screening and Diagnostic Evaluation: CAN Consensus Statement (1998) (13)
- Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia (2012) (13)
- The machine measured characteristics of tardive dyskinesia (1989) (13)
- The “Alzheimer's Type” Profile of Semantic Clustering in Amnestic Mild Cognitive Impairment (2014) (12)
- Speech and Language Alterations in Dementia Syndromes (1989) (12)
- ADCS Prevention Instrument Project: Behavioral Measures in Primary Prevention Trials (2006) (12)
- Healthybrains.org: From Registry to Randomization. (2016) (12)
- Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease (2013) (12)
- Diagnosis of Rare Dementia Syndromes: An Algorithmic Approach (1990) (12)
- Psychopathology and epilepsy: an outpatient consultation-liaison experience. (1988) (12)
- Reconsidering diagnostic criteria for dementia with lewy bodies. Highlights from the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia, September 17-20, 2003, Newcastle Upon Tyne, United Kingdom. (2004) (12)
- A Placebo-Controlled, Parallel Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. (2020) (12)
- Tautological tangles in neuropathologic criteria for dementias associated with Lewy bodies (1996) (12)
- Measuring Outcomes in Alzheimer’s Disease Research (1999) (11)
- Searching for methods to detect, prevent, and treat Alzheimer's disease. (2005) (11)
- New tests for dementia. (2000) (11)
- MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints (2021) (11)
- Novel targets for Alzheimer's disease treatment (2014) (11)
- Emotional consequences of focal brain lesions: an overview (2000) (11)
- Obsessive-compulsive disorders in association with focal brain lesions (2000) (11)
- D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer ’ s disease (2006) (11)
- Food for thought: Souvenaid in mild Alzheimer’s disease. (2012) (11)
- Neuropsychiatric Assessment and Intervention in Alzheimer's Disease (1996) (11)
- The clinician-scientist in neuropsychiatry: a position statement from the Committee on Research of the American Neuropsychiatric Association. (1998) (11)
- Lateral asymmetries of tardive dyskinesia in schizophrenia (1988) (11)
- Clinical variants of tardive dyskinesia (1988) (10)
- Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers (2020) (10)
- Pseudobulbar affect - A disabling but under-recognised consequence of neurological disease and brain injury (2013) (10)
- Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report (2020) (10)
- Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer’s Disease: A Retrospective Analysis (2010) (10)
- Alzheimer's Disease and Related Disorders Annual - 2001 (2001) (10)
- Parkinson's disease. (1997) (10)
- Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience (2018) (10)
- Depression in Parkinson's disease (2002) (10)
- A window on the role of dopamine in addiction disorders (2000) (10)
- Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. (2007) (10)
- Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease (2015) (10)
- Focal lesions and psychosis (2000) (9)
- Multiple system atrophy presenting with language impairment (2006) (9)
- Emotional behavior in acute brain lesions (2000) (9)
- Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease (2020) (9)
- Vascular Dementia: Clinical Assessment, Neuropsychological Features, and Treatment (1997) (9)
- FLAME: A computerized neuropsychological composite for trials in early dementia (2020) (9)
- Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings. (2002) (9)
- The Impact of Depressive Symptoms on Patients With Alzheimer Disease (2003) (9)
- Dementia : a global approach (2010) (9)
- Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™). (2014) (9)
- Dementia syndromes: neurobehavioral and neuropsychiatric features. (1987) (9)
- ADCS Prevention Instrument Project: Development of a Brief Verbal Memory Test for Primary Prevention Clinical Trials (2006) (9)
- Psychotropic drugs and epilepsy (1986) (9)
- Introduction to the Neuropsychiatry of Limbic and Subcortical Disorders (1997) (9)
- Detecting dynamic (4D) profiles of degenerative rates in Alzheimer's disease patients, using high-resolution tensor mapping and a brain atlas encoding atrophic rates in a population (2001) (9)
- Propositional Density and Apolipoprotein E Genotype among Persons at Risk for Familial Alzheimer’s Disease (2011) (8)
- Neuropsychiatric and cognitive disorders in other parkinsonian disorders (2013) (8)
- PSYCHIATRIC MANIFESTATIONS IN DEMENTIA (2007) (8)
- A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia (2000) (8)
- [Passage of language dominance to the right hemisphere: interpretation of delayed recovery after global aphasia]. (1980) (8)
- Dementia: Definition, Classification, and Differential Diagnosis (1984) (8)
- Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. (1994) (8)
- Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease (2011) (8)
- Tardive dystonia: clinical spectrum and novel manifestations. (1988) (8)
- Alzheimer's disease: cognitive and behavioral pharmacotherapy. (1997) (8)
- Creutzfeldt-Jakob disease with mixed transcortical aphasia: insights into echolalia. (1994) (8)
- Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease (2018) (8)
- Psychosis in basal ganglia disorders : Psychosis in neurologic diseases (1992) (8)
- Erratum: 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease (Brain (2006) 127, part 11, (2867-2873) DOI: 10.1093/brain/awl274) (2007) (8)
- Estimating Progression Rates Across the Spectrum of Alzheimer’s Disease for Amyloid-Positive Individuals Using National Alzheimer’s Coordinating Center Data (2021) (8)
- Clinical trials in neurology : design, conduct, analysis (2012) (8)
- Dementia With Lewy Bodies: Clinical, Pathological and Treatment Issues (1996) (8)
- Value-Generating Exploratory Trials in Neurodegenerative Dementias (2021) (8)
- An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home (2020) (8)
- Current perspectives in Alzheimer's Disease (1998) (8)
- Patterns of neuropsychological performance among forms of subcortical dementia: A case study approach (1994) (8)
- Consent for dental therapy in severely ill patients. (1988) (8)
- Neuropsychology of Memory, 2nd ed (1994) (8)
- Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia. (2016) (8)
- Drug Development in Alzheimer’s Disease—The Role of Default Mode Network Assessment in Phase II (2017) (8)
- Visuoconstructional impairment in dementia syndromes. (1991) (7)
- Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. (1999) (7)
- Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. (2017) (7)
- Principles of neuropsychiatry: Towards a neuropsychiatric epistemology (1999) (7)
- Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. (1995) (7)
- Speech and Language (2007) (7)
- Early cognitive impairment (2013) (7)
- Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease (2017) (7)
- Psychosis in neurologic diseases (1992) (7)
- Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory (2016) (7)
- Case report: A global sequential processing disorder following head injury: A possible role for the right hemisphere in serial order behavior (1979) (6)
- The neuropsychiatric burden of neurological diseases in the elderly (2005) (6)
- Neuroimaging in the Dementia Assessment: Is It Necessary? (2000) (6)
- Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease (2015) (6)
- Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. (2013) (6)
- Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 (2018) (6)
- Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease (2004) (6)
- Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. (2019) (6)
- The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive. (2013) (6)
- Network-based assessment of collaborative research in neuroscience (2018) (6)
- Stakeholders’ Perspectives on Preclinical Testing for Alzheimer’s Disease (2015) (6)
- 617 Metrifonate in Alzheimer's disease - results of a dose-finding study (1996) (6)
- Dementia of the Alzheimer Type: Challenges of Definition and Clinical Diagnosis (1988) (6)
- Understanding changes in cholinergic function: implications for treating dementia. (2002) (6)
- The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory (2020) (5)
- Alzheimer's disease: translating neurochemical insights into clinical benefits. (2000) (5)
- AlzGPS: A Genome-wide Positioning Systems Platform to Catalyze Multi-omics for Alzheimer’s Therapeutic Discovery (2020) (5)
- Use of atypical antipsychotics in the elderly. (2008) (5)
- Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease (2010) (5)
- Measuring Disease Modification in Alzheimer's Disease (2007) (5)
- Neuropsychiatric features of dementia (2009) (5)
- 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in Alzheimer's diagnosis: time for technology transfer. (2002) (5)
- Melancholia: A Disorder of Movement and Mood: A Phenomenological and Neurobiological Review (1997) (5)
- The evaluation of mood and behavior in patients with focal brain lesions (2000) (5)
- D-3 receptor agonists: combined action neurologic and neuropsychiatric agents. (1999) (5)
- Assessment of mood, affect, and personality. (1989) (5)
- Temporal lobe behavioral syndromes (2000) (5)
- Mania and manic-like disorders (2000) (5)
- EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. (2014) (5)
- Alzheimer's Disease and Related Disorders Annual - 2002 (2002) (5)
- Vascular dementia and dementia of Alzheimer-type cognition. (1989) (5)
- Genetic Risk of Alzheimer’s Disease: Three Wishes Now That the Genie is Out of the Bottle (2018) (5)
- A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease (2022) (5)
- Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment (2014) (5)
- Genotype — Proteotype — Phenotype Relationships in Neurodegenerative Diseases (2005) (5)
- The Dementias: Diagnosis, Treatment and Research, 3rd ed (2004) (4)
- Neuropsychiatric disturbances in alzheimer's disease and other dementias: Recognition and management (1996) (4)
- CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) (4)
- Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation (2022) (4)
- DEPRESSION IN DEMENTIA (2001) (4)
- Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia (2020) (4)
- Neuropsychiatry and society. (1996) (4)
- Parkinson's disease and related parkinsonian syndromes (2003) (4)
- Treatment of Depression in the Patient with Parkinson's Disease. (1998) (4)
- Comparison of neuropsychological and neurobehavioral functioning in FTD and AD patients (1996) (4)
- Multicultural Perspectives on the Neuropsychological and Neuropsychiatric Assessment and Treatment of the Elderly (2000) (4)
- Symptomatic Cognitive Enhancing Agents (2016) (4)
- P1-455 Meta-analysis of Neuropsychiatric Inventory (NPI) domains in three 6-month trials of memantine in moderate to severe AD (2006) (4)
- Neuropsychiatric features of dementia with Lewy bodies (2006) (4)
- Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. (2010) (4)
- Bipolar syndromes following brain trauma (1997) (4)
- Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression (1996) (4)
- [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies (2012) (4)
- The Pathogenesis of Alzheimer’s Disease: General Overview (2007) (4)
- Neuropathologic correlates of trial-related instruments for Alzheimer's disease. (2014) (4)
- Erratum: Early behavioural changes in familial Alzheimers disease in the Dominantly Inherited Alzheimer Network (Brain (2015) 138 (103645) (10.1093/brain/awv004)) (2015) (4)
- Pathways to neuropsychiatry. (1995) (4)
- Neuropsychiatric Inventory (NPI) 1994 (2004) (4)
- Psychiatric Aspects of Parkinson’s Disease, Parkinson’s Disease with Dementia, and Dementia with Lewy Bodies (2004) (4)
- Methodological issues in studying secondary mood disorders (2000) (3)
- Original Article Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease (2014) (3)
- Atypical Dementia Syndrome in an Elderly Man (1987) (3)
- Comparative Safety and Tolerability of Alzheimer’s Disease Treatments (2008) (3)
- Using bibliometrics to evaluate outcomes and influence of translational biomedical research centers (2021) (3)
- Progress in the management of behavioral symptoms in Alzheimer's disease (1999) (3)
- Alzheimer's Disease and Related Disorders (2005) (3)
- Frontotemporal dementia and the orbitofrontal cortex (2010) (3)
- Integrating Symptomatic- and Disease-Modifying Treatments (2008) (3)
- TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 6b. BEHAVIORAL DISORDERS AND CAREGIVERS' REACTION IN TAIWANESE PATIENTS WITH ALZHEIMER'S DISEASE (2009) (3)
- Neural correlates of violent behavior (2000) (3)
- Efficacy and safety of AXS‐05, a novel, oral, NMDA‐receptor antagonist with multimodal activity, in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1, a phase 2/3, double‐blind, active and placebo‐controlled trial (2020) (3)
- Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Establishing a national biomarker database: Utility and incentives (2009) (3)
- The neuropsychiatry of dementing disorders (2003) (3)
- Language and Communication in Non-Alzheimer's Dementias (1998) (3)
- Is Alzheimer's Disease Drug Development Broken? What Must Be Improved. (2014) (3)
- Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease (2016) (3)
- Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. (2016) (3)
- Genotype, proteotype, phenotype relationships in neurodegenerative diseases. Highlights from the 21st Ipsen Foundation Alzheimer's Disease Symposium, September 13, 2004, Paris, France. (2005) (3)
- Biomarkers in Alzheimer's Disease—Perspectives for the Future (2010) (3)
- Alzheimer's disease: clinical trials and the amyloid hypothesis. (2011) (3)
- Effect of memantine on behavioral outcomes in Alzheimer’s disease (2005) (3)
- Tardive movement disorders (1990) (3)
- Early cortical change in Alzheimer's disease detected using cortical pattern matching and a disease-specific population-based brain atlas (2000) (3)
- Motility, behaviour and the brain. (1998) (3)
- Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach (2020) (3)
- Dementia diagnosis and therapy in the elderly. (1992) (3)
- Infrequent skin reactions at the application site of the rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): Analysis of two clinical studies revealed most were tolerable and manageable across all doses (2013) (3)
- Effective Pharmacologic Management of (2007) (3)
- The Neurological Side of Neuropsychology (1997) (3)
- P1-318 Metabolic patterns associated with the clinical response to galantamine therapy: an FDG-PET study (2004) (3)
- HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis (2020) (2)
- Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. (2020) (2)
- Clinical features and treatment of Alzheimer's disease (1990) (2)
- Involuntary Emotional Expression Disorder (2007) (2)
- Depression and lesion location in stroke (2000) (2)
- Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players (2022) (2)
- Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (2)
- Alzheimer's disease management. (1998) (2)
- Comparison of two cognitive screening measures in differentiating functioning among community dwelling African-American seniors (1997) (2)
- Appendix C: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology (2007) (2)
- Drug treatment for Alzheimer's disease. (1998) (2)
- TRC-PAD: USING RUN-IN DATA FOR SCREEN FAILURE REDUCTION (2016) (2)
- Comprar Clinical Trials In Neurology. Design, Conduct, Analysis | Bernard Ravina | 9780521762595 | Cambridge University Press (2012) (2)
- OPTIMIZING MEASUREMENT OF AGITATION AND AGGRESSION IN DEMENTIA (2017) (2)
- P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease (2008) (2)
- Alzheimer's Disease Clinical Trials: Where are we now? (2006) (2)
- Affective Computing for Late-Life Mood and Cognitive Disorders (2021) (2)
- Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods (2018) (2)
- PHASE II CLINICAL TRIAL WITH AN AMPA-POSITIVE ALLOSTERIC MODULATOR (S 47445): BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS SUFFERING FROM ALZHEIMER’S DISEASE AT MILD TO MODERATE STAGES WITH DEPRESSIVE SYMPTOMS (2017) (2)
- Neuropsychiatric aspects of cognitive impairment (2016) (2)
- Treatable dementias. (1987) (2)
- Treatable dementias: differential diagnosis and obstacles to recognition. (1985) (2)
- Review of an Emerging Concept (2017) (2)
- Long-term treatment for patients with Alzheimer disease (2004) (2)
- 1 2 3 D mapping of language networks in clinical 3 and pre-clinical Alzheimer ’ s disease 4 (2007) (2)
- Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease (2010) (2)
- GETTING DONEPEZIL INTO THE NURSING HOME ‐ Response to the Editor (2003) (2)
- Extended-Release Memantine (28 mg, Once Daily) and Sustained Behavioral Improvement: Post Hoc Responder Analysis from a Randomized Trial in Patients with Moderate to Severe Alzheimer's Disease (P04.197) (2012) (2)
- Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials (2012) (2)
- New Advances in the Treatment of Alzheimer's Disease (1998) (2)
- MAINTENANCE OF COGNITIVE IMPROVEMENT TREATMENT RESPONSE WITH MEMANTINE AND DONEPEZIL: POST HOC ANALYSES FROM A PLACEBO-CONTROLLED STUDY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE (2017) (2)
- Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults (2020) (2)
- THE DIAGNOSIS AND MANAGAMENT OF DEMENTIA Authors: (2005) (2)
- 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI (2010) (2)
- Comprar Dementia | Jeffrey L. Cummings | 9780521857765 | Cambridge University Press (2010) (2)
- ffective Pharmacologic Management of lzheimer ’ s Disease (2007) (2)
- The role of apolipoprotein E testing in the diagnosis of Alzheimer's disease. (1998) (2)
- Managing Functional and Cognitive Decline in Patients with Mild-to-Moderate Alzheimer's Disease: A 48-Week, Randomized, Double-Blind Evaluation of 13.3 mg/24 h (15 cm{superscript 2}) Versus 9.5 mg/24 h (10 cm{superscript 2}) Rivastigmine Patch (P04.193) (2012) (2)
- Acute confusional states and delirium (2000) (2)
- Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment (2022) (2)
- A RANDOMIZED DOUBLE-BLIND COMPARISON OF NORTRIPTYLINE PLUS PLACEBO VS. NORTRIPTYLINE PLUS PERPHENAZINE IN THE TREATMENT OF PSYCHOTIC MAJOR DEPRESSION IN LATE LIFE (1999) (2)
- Alzheimer’s prevention registry: A shared resource to the scientific community to facilitate enrollment in studies (2015) (2)
- Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force (2018) (1)
- Selegiline in the treatment of akathisia, tardive dyskinesia, and negative schizophrenic symptoms (1992) (1)
- Dementia: An overview (2000) (1)
- Physostigmine in wilson disease (1978) (1)
- Creutzfeldt-Jakob disease and other prion disorders (2003) (1)
- Dementia prevention in memory clinics: recommendations from the European task force for brain health services (2023) (1)
- P2-373 3D mapping of gray matter atrophy in semantic dementia and frontal variant frontotemporal dementia (2006) (1)
- Dementia: Assessing behavior in dementia across cultures (2010) (1)
- Managing Functional and Cognitive Decline in Patients with Mild-to-Moderate Alzheimer's Disease: A 48-Week, Randomized, Double-Blind Evaluation of 13.3 mg/24 h (15 cm²) Versus 9.5 mg/24 h (10 cm²) Rivastigmine Patch (P04.193) (2012) (1)
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures (2014) (1)
- Dementia: The United States of America (2010) (1)
- CONTEMPO UPDATES LINKING EVIDENCE AND EXPERIENCE Alzheimer Disease (2002) (1)
- mavanserin for patients with Parkinson ’ s disease psychosis : a randomised , placebo-controlled phase 3 trial (2013) (1)
- Frontotemporal Degeneration , the Next Therapeutic Frontier : Molecules and Animal Models for FTD drug development ( Part 1 of 2 articles ) (2013) (1)
- Disease modification and Neuroprotection in neurodegenerative disorders (2017) (1)
- Antipsychotic efficacy and good tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020) (2013) (1)
- Update on Alzheimer's Disease: One Hundred Years After Dr. Alois Alzheimer (2008) (1)
- Dealing with writer's block in an older man: depression, Parkinson's disease, or both? (1991) (1)
- Neurodegenerative Disorders as Proteinopathies: Phenotypic Relationships (2005) (1)
- Introduction (2008) (1)
- O1-05-06 The dementia and disability in thai elderly project: Prevalence of mild cognitive impairment with one year follow up and the prevalence of dementia in community dwelling thai elderly (2007) (1)
- Moderate and Severe Alzheimer ' s Disease Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil ( 23 mg ) in (2012) (1)
- Clinical Trials in Dementia (2007) (1)
- Alexia and agraphia after Luria (1989) (1)
- IC-P-090 Elevated hippocampal myo-inositol in subjects with or at-risk for familial AD (2006) (1)
- Dementia with Lewy Bodies: Biographical note on F. H. Lewy (1996) (1)
- Commentary on: L-Methylfolate, Methylcobolamine, and N-Acetylcysteine in the Treatment of Alzheimer's Disease-Related Cognitive Decline (2010) (1)
- Diagnostic rates and amyloid positivity vary by definition of mild cognitive impairment (2020) (1)
- Significance and Phenomenology (2017) (1)
- GAP-NET: SITE NETWORKS FOR EFFICIENT TRIALS RECRUITMENT (2016) (1)
- EXPLORING NOVEL TREATMENT OPTIONS: COGNITIVE DECLINE IN ALZHEIMER'S DISEASE (2010) (1)
- Anxiety is associated with brain amyloidosis in cognitively normal and mild cognitive impairment subjects: A [18F]flutemetamol PET study (2015) (1)
- COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS (2014) (1)
- High-dose 13.3mg/24h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer's disease with and without concomitant memantine use (2013) (1)
- A transdermal patch in Alzheimer disease (2007) (1)
- In Memoriam—D. Frank Benson, MD (1997) (1)
- Neuropathologic correlates of trial-related clinical assessments (2010) (1)
- A tensor based morphometry study of patients with cognitive impairment and dementia in parkinson's disease (2009) (1)
- Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index (2020) (1)
- Alzheimer's disease Speech and language in progressive nonfluent aphasia compared with early (2006) (1)
- P1-315 Functional and behavioral effects of memantine in Alzheimer's disease (2004) (1)
- THE EFFECTS OF MEMANTINE ADDED TO CHOLINESTERASE INHIBITORS ON NPI BEHAVIORAL DOMAINS: POOLED POST HOC ANALYSIS OF THREE RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH MODERATE TO SEVERE AD (2018) (1)
- Affective Computing for Brain Health Disorders (2021) (1)
- P1-433 PET metabolic correlates of apathy in Alzheimer’s disease (2006) (1)
- Comprar Textbook of Geriatric Neuropsychiatry. 3rd. Edi. | C. Edward Coffey | 9781585623716 | American Psychiatric Publishing (2011) (1)
- Behavioral Manifestations of Alzheimer’s Disease (2001) (1)
- XANAMEMTM: A NOVEL 11B-HSD1 INHIBITOR WITH POTENTIAL TO PROVIDE DURABLE SYMPTOMATIC AND DISEASE MODIFYING BENEFITS IN ALZHEIMER’S DISEASE (2016) (1)
- Neuropsychiatric assessment of patients with dementia (2003) (1)
- P2-374 MR-guided 3D PET mapping of longitudinal changes in regional cerebral metabolism of normal subjects (2006) (1)
- Neuropsychiatric Symptoms in Dementia Patients (1999) (1)
- Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. (2022) (1)
- Thalamic behavioral syndromes (2000) (1)
- Depression, Psychosis, and Agitation in Stroke (2017) (1)
- IC-P-075 Cognitive processing speed and myelin breakdown in older individuals (2006) (1)
- Encephalitis lethargica: Lessons for neuropsychiatry (2001) (1)
- P4-314: Evaluating neuropsychiatric symptoms in Alzheimer's disease: A novel approach using bubble plots to evaluate donepezil treatment effects (2008) (1)
- Fellowship Programs in Behavioral Neurology (1995) (1)
- Alzheimer's disease (2015) (1)
- Methionine sulfoxide, an index of oxidative stress, measured in plasma of persons with familial Alzheimer's disease mutations (2010) (1)
- Frontal lobe degenerations (1994) (1)
- THE MILD BEHAVIORAL IMPAIRMENT CHECKLIST (MBI-C): A NEW RATING SCALE FOR NEUROPSYCHIATRIC SYMPTOMS AS EARLY MANIFESTATIONS OF NEURODEGENERATIVE DISEASE (2016) (1)
- Erratum: Dextromethorphan-quinidine for agitation in Alzheimer disease [letter reply] (JAMA (2016) 315:11 (1166-1167)) (2016) (1)
- Is it a cortical or a subcortical dementia? The answer makes a difference in nursing interventions and patient prognosis (1986) (1)
- A tensor-based morphometry study of brain volume changes in symptomatic and pre-symptomatic patients with familial Alzheimer's disease (2010) (1)
- Novel CSF biomarkers for frontotemporal lobar degeneration with lesions immunoreactive to TDP-43 (FTLD-TDP) (1)
- Extrapyramidal syndromes in the elderly: diagnosis and management. (1989) (1)
- Featured Article Alzheimer's drug-development pipeline: 2016 (2016) (1)
- New IPA Criteria for Agitation in Cognitive Impairment. (2015) (1)
- 427 - HARMONY study: pimavanserin significantly reduces risk of relapse of dementia-related psychosis (2020) (1)
- Progress in Neurotherapeutics and Neuropsychopharmacology: Author Index (2008) (1)
- Roles in Alzheimer Disease Apolipoprotein E and Apolipoprotein E Receptors : Normal Biology and Subject Collection The Biology of Alzheimer Disease Animal Models of Alzheimer Disease (2012) (1)
- Chapter 25 – Aphasia (2003) (1)
- The Role of Positron Emission Tomography in the Diagnosis of Alzheimer's Disease (2004) (1)
- The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs (2020) (1)
- Brain volume changes with divalproex sodium in Alzheimer's disease (2010) (1)
- Panel discussion (1998) (1)
- Encephalitis lethargica [4] (1995) (1)
- Prolonged psychosis with first-rank symptoms following metrizamide myelography. (1986) (1)
- The Advantages of FTD Drug Development ( Part 2 of FTD : The Next Therapeutic Frontier ) (2013) (1)
- REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING (2014) (1)
- Dementia with parkinsonism: what is the diagnosis? (2004) (1)
- Diagnosis and Treatment of Dementia (2003) (1)
- BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING APABETALONE IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME (2019) (1)
- The neuropsychiatric disturbances in demential disorders or behavioral and psychological symptoms of dementia (2007) (1)
- O3-06-06 [18F]FDDNP-PET imaging in persons at-risk for familial AD (2006) (1)
- O4-04-01 A hierarchical approach to practical assessment of cognitive decline in the elderly (2006) (1)
- Barriers to Behavioral Research on Dementia (1996) (1)
- Prosodic changes in speech following brain damage: Acoustic and neuroradiographic measures (1988) (1)
- Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes (2014) (0)
- Quetiapineof its Clinical Potential in the Management of Psychotic Symptoms in Parkinson's Disease (2000) (0)
- Diagnostic criteria for Depression of Alzheimer disease (DAD) (2003) (0)
- Cognition, Ventricular Size, and Leuko-Araiosis (2017) (0)
- Neuropsychiatric Inventory with Caregiver Distress Scale 1998 (2004) (0)
- Idalopirdine, a 5-HT6 antagonist in Phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: the observed case analyses of the Phase II study (2016) (0)
- Treatment of agitation in people with Alzheimer's dementia: Rationale for the clinical investigation of AVP-923 (dextromethorphan/quinidine) (2013) (0)
- Midlateney auditory evoked responses : differential abnormality of P 1 in Aizheimer ' s disease (2002) (0)
- WARFARIN IN SNEDDON'S SYNDROME. AUTHORS' REPLY (1996) (0)
- UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY (2014) (0)
- Dementia with Lewy Bodies: Foreword (1996) (0)
- Erratum: The American Psychiatric Press Textbook of Geriatric Neuropsychiatry (The American Journal of Geriatric Psychiatry (1996)) (1996) (0)
- Behavioral Neurology: A Practical Approach (1986) (0)
- Cognitive Neurorehabilitation: Pharmacologic interventions for cognition in dementia (2008) (0)
- Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program (2018) (0)
- IC-P3-207: Decreased activation in the left medial parietal lobe in presymptomatic FAD mutation carriers in fMRI during an unrelated word pair memory task (2008) (0)
- Mild Cognitive Impairment and Prodromal Alzheimer’s Disease (2017) (0)
- Reply: Spect and dementia (1992) (0)
- Neuropsychiatric symptom profiles in Mild Cognitive Impairment and Alzheimer's disease (2010) (0)
- D. Frank Benson, M.D.: Biography and overview of contributions (1999) (0)
- Do neurologists have a future in neuroimaging? (1998) (0)
- P1-002 Robust response to memantine treatment when functional and behavioral efficacies are combined with cognition (2004) (0)
- Hippocampal atrophy and lateral ventricle enlargement in Parkinson's disease subjects with mild cognitive impairment (2010) (0)
- SympoSia S 1-APECS TRIAL OF THE BACE 1 INHIBITOR VERUBECESTAT FOR PRODROMAL ALZHEIMER ’ S DISEASE (2018) (0)
- Dementia: Further reading (2010) (0)
- 103 - A global perspective on dignity-based psychogeriatric care: An urgent call for a Convention on rights for older people (2021) (0)
- O1-02-05: Automated longitudinal 3D mapping of hippocampal ADAS-cog delayed recall effects in 293 normal elderly, MCI and Alzheimer's disease subjects (2008) (0)
- ADVERSE EVENTS AND THEIR COSTS IN ELDERLY PATIENTS RECEIVING DIVALPROEX SODIUM OR LITHIUM CARBONATE (1999) (0)
- P2-300 In vivo quantification of neuronal loss and neuropathological deposition in Alzheimer’s disease with PET (2006) (0)
- Introduction to Neurotherapeutics and Neuropsychopharmacology (2006) (0)
- Progress in Neurotherapeutics and Neuropsychopharmacology: Contributors (2006) (0)
- P4-329: Post HOC responder analyses of Memantine treatment on behavioral disturbances in patients with moderate to severe Alzheimer's disease (2008) (0)
- and Report of 22 Cases (1986) (0)
- NOVEL RECRUITMENT STRATEGIES FOR CLINICAL TRIALS: A PRELIMINARY REPORT FROM THE GLOBAL ALZHEIMER’S PLATFORM NETWORK (GAP-NET) (2017) (0)
- Drug treatment and behavior (2013) (0)
- Response to commentaries (2000) (0)
- Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch (2015) (0)
- COGNITIVE IMPAIRMENT ANTIDEMENTIA DRUGS IN A GERIATRIC CLINIC OF A PHASE-3 TRIAL (APECS) TO EVALUATE THE PRODROMAL AD (0)
- Primary Psychiatry: Introduction (2008) (0)
- Clinical Assessment, Neuropsychological Features, and Treatment (1997) (0)
- IC-P-085 MR-guided 3D PET mapping of longitudinal changes in regional cerebral metabolism of normal subjects (2006) (0)
- Dementia with Lewy Bodies: Plate section (1996) (0)
- Introduction/Alzheimer’s Disease Management (1998) (0)
- Discrepancies in the detection of early impairment in elderly individuals: Implications for the clinic and research (2020) (0)
- Editorial Board (1992) (0)
- Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study (2020) (0)
- preference following brain injury . Hypersexuality or altered sexual (2004) (0)
- IC-P3-165: 3D comparison of low, intermediate and advanced hippocampal atrophy in MCI (2008) (0)
- The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study (2013) (0)
- How do different economic models of care impact the care of patients with dementia ? (2003) (0)
- 3-D mapping of associations amongst amyloid-PET and CSF biomarkers and hippocampal morphology (2009) (0)
- Hippocampal Atrophy and Lateral Ventricle Enlargement in Parkinson's Disease Subjects With Mild Cognitive Impairment (2010) (0)
- Evidentiary Standards for Neurological Drugs and Biologics Approval (2012) (0)
- Cognitive characteristics of older adults with history of concussion (2020) (0)
- Clinical Trials in Neurology: Contents (2012) (0)
- Pimavanserin and dementia-related psychosis (2022) (0)
- Automated diagnostic classifiers for cognitively normal and mild cognitive impairment subjects using imaging, genotyping, and gene expression (2011) (0)
- IC-P2-072: Automated 3D mapping of caudate atrophy and ventricular enlargement in Parkinson's disease with and without dementia (2008) (0)
- Behavioral correlates of cognitive decline in normal aging and prodromal Alzheimer’s disease (2015) (0)
- Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project (2021) (0)
- Progress in Neurotherapeutics and Neuropsychopharmacology (2009) (0)
- Intracerebroventricular bethanecol for the treatment of Alzheimer??s disease (1991) (0)
- Anxiety is associated with brain amyloidosis in cognitively normal and mild cognitive impairment subjects: A [18F]flutemetamol PET study (2015) (0)
- Metabolic responses to donepezil therapy in Alzheimers disease (2000) (0)
- Update of pharmacologic management of behavioral disturbances in Alzheimer's disease (2000) (0)
- Alzheimer's disease and related disorders annual 5 / (2014) (0)
- The impact of ApoE alleles on age-related myelin breakdown (2005) (0)
- Challenges and Opportunities to Conduct Global Alzheimer’s Disease Clinical Trials (2014) (0)
- CHAPTER 19 – AFFECTIVE DISORDERS (2007) (0)
- Memantine ER and Donepezil Treatment Maintains Cognitive Improvements Versus Donepezil Monotherapy: Post Hoc Analyses From a Placebo-controlled Study in Patients with Moderate-to-Severe Alzheimer’s Disease (P6.176) (2018) (0)
- New paradigms in the treatment of Alzheimer's disease. (2006) (0)
- Infections and dementia: the view from a developing nation (2010) (0)
- Contents Vol. 37, 2014 (2014) (0)
- Effects of ApoE genotype but not of FAD mutation status in BOLD activation during a novelty encoding task (2009) (0)
- Comprar The Human Frontal Lobes: Functions and Disorders | Jeffrey L. Cummings | 9781593853297 | Taylor & Francis Ltd (2007) (0)
- Dementia with parkinsonism. (2004) (0)
- Classification of Dementias and Cognitive Disorders (2003) (0)
- Our thanks to reviewers in 2011 (2011) (0)
- Gene expression correlates of hippocampal atrophy across in cognitively normal elderly and MCI (2010) (0)
- High-dose 13.3 mg/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis (2012) (0)
- T r anslational research (2007) (0)
- Dementia with Lewy Bodies: Group photograph (1996) (0)
- Incorrect Name in Conflict of Interest Disclosure. (2016) (0)
- A tensor-based morphometry study of patients with cognitive impairment and dementia in Parkinson's disease (2009) (0)
- P4-550 ASSOCIATION OF PLASMA-SOLUBLE TREM2WITHNEOCORTICALAMYLOID-b LOAD IN COGNITIVELY NORMAL ELDERLY PARTICIPANTS (2019) (0)
- Dementia diagnosis and therapy in the elderly : Neuropsychiatry (1992) (0)
- Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients (2023) (0)
- Altered Behavior Associated with Datnage to the Ventrotnedial Hypothalatnus: a Distinctive Syndrotne (1988) (0)
- Dementia: Molecules, Methods, and Measures (1993) (0)
- The mental status examination. (1993) (0)
- CSF Abeta and Tau associations with 3-D hippocampal radial distance mapped in 282 ADNI subjects (2009) (0)
- Clinical trials for psychotropic agents in Parkinson’s disease using psychosis as a model (2010) (0)
- P.5.a.010 The effect of memantine on distinct behaviour syndromes in moderate to severe Alzheimer's disease patients (2006) (0)
- A SUMMARY OF THE RATIONALE AND DESIGN OF THE HARMONY STUDY: A PHASE 3 STUDY TO EVALUATE PIMAVANSERIN FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS (2018) (0)
- Dementia with Lewy Bodies: Guidelines for the selection of cortical areas for the evaluation of Lewy body distribution and proposed diagnostic rating protocol (1996) (0)
- Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume (2019) (0)
- Original Article Neuropathologic correlates of trial-related instruments for Alzheimer's disease (2014) (0)
- Corrigenda (1813) (0)
- Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate ad: combined sub-group analyses from two Phase 3 trials (2016) (0)
- Neuropsychological performance and demographic variables predict familial Alzheimer genetic status in a Spanish speaking sample (2010) (0)
- IC-P-018 3D mapping of gray matter atrophy in semantic dementia and frontal variant frontotemporal dementia (2006) (0)
- Index to Volume 138 (1981) (0)
- Neuropsychiatric Symptoms in Alzheimer’s Disease: Assessment and Management (2002) (0)
- Use of antipsychotic drugs in dementia : Jeremy A Sable and Dilip V Jeste (2001) (0)
- An expert panel review of clinical challenges in neurology (2012) (0)
- Introduction to Special Issue Psychiatric Aspects of Parkinson's Disease, Parkinson's Disease With Dementia, and Dementia With Lewy Bodies (2004) (0)
- PATIENT-DERIVED MICROGLIA CELLULAR MODEL TOWARDS BETTER UNDERSTANDING NEUROIMMUNOLOGY OF ALZHEIMER’S DISEASE (2019) (0)
- Neuropsychiatric evaluation in dementia. (2008) (0)
- IC-P-069 Decreased fractional anisotropy in the fornix of presymptomatic carriers of FAD mutations (2006) (0)
- IDALOPIRDINE, A 5-HT6 ANTAGONIST IN PHASE III DEVELOPMENT AS ADJUNCTIVE THERAPY TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE: BASELINE DATA FROM THE ONGOING STARSHINE STUDY (2016) (0)
- Progress in Neurotherapeutics and Neuropsychopharmacology: Progress in Neurotherapeutics and Neuropsychopharmacology 2008 (2008) (0)
- Differential Diagnosis in Neuropsychiatry (1985) (0)
- APABETALONE (AN EPIGENETIC BET-INHIBITOR SMALL MOLECULE) AND EFFECTS ON COGNITION IN DIABETES PATIENTS WITH CARDIOVASCULAR DISEASE (2018) (0)
- Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study (2012) (0)
- Pharmacologic Efficacy in Neuropsychiatry (2015) (0)
- Atypical Alzheimer’s Disease, Mixed Dementia, and Amyloid Angiopathy (2017) (0)
- Parkinson’s disease: pathology, anatomy, and behavior (2013) (0)
- Perspectives on the benefits and harms of preclinical testing for Alzheimer's disease (2013) (0)
- DOPAMINE RECEPTOR CORRELATES OF PSYCHOSIS IN DEMENTIA (1999) (0)
- Donepezil for nursing home patients with dementia: A reinterpretation of the evidence. Authors' reply (2003) (0)
- Important Concepts in Parkinson's Disease: Can Online Education Improve Physician Knowledge on Neuropsychiatric Complications? (P1.025) (2016) (0)
- Dr. Cummings Replies (2006) (0)
- Hippocampal Atrophy and Lateral Ventricle Enlargement in Parkinson's Disease Subjects with Mild Cognitive Impairment (2010) (0)
- HIPPOCAMPAL TEXTURE IN HEALTHY COGNITION AND MILD COGNITIVE IMPAIRMENT: THE IMPACT OF AMYLOID BURDEN AND SEX (2018) (0)
- IC-P3-223: Automated longitudinal 3D mapping of hippocampal ADASCPG delayed recall effects in 293 normal elderly, MCI and AD subjects (2008) (0)
- P4.021 Robust response to memantine treatmentwhen functional and behavioral results are combined with cognition (2004) (0)
- EPIGENOMIC PROFILINGOF33QN1IPSCS THROUGHOUT NEURONAL DIFFERENTIATION: IMPLICATIONS FOR STUDIES OF AGE-RELATED NEURODEGENERATIVE DISORDERS DISEASE (LOAD) IN THE CONTEXT OF AGING (2019) (0)
- Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials (2015) (0)
- Behavioral reserve in mild cognitive impairment and mild Alzheimer's disease (2012) (0)
- Oral O1-04: Therapeutics and Therapeutic Strategies: Clinical Trial Results P84 O1-03-08 NEURONAL IGF-1 RESISTANCE PROTECTS AGAINST PREMATURE DEATH AND REDUCES b-AMYLOID ACCUMULATION IN TG2576 MICE (0)
- Neuropsychiatric Syndromes in the Elderly: Pharmacologic Management (1989) (0)
- Contents Vol. 44, 2017 (2018) (0)
- FP46-TH-05 Glomerular filtration rate and cognitive impairment in adults: data from the dementia and disability project in Siriraj Hospital, Thailand (2009) (0)
- CSF Abeta and tau, hippocampal atrophy and lateral ventricle enlargement in Parkinson's disease with and without mild cognitive impairment (2010) (0)
- β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification (2020) (0)
- Altered tau processing: its role in development of dementia in Alzheimer's disease and Lewy body disease (1996) (0)
- Contents Vol.45, 2018 (2018) (0)
- 41-2 Cholinergic treatment of behavioral disturbances in Alzheimer's disease (1997) (0)
- 183 Cholinergic treatment of behavioral disturbances in Alzheimer's disease (1996) (0)
- VALIDATION OF A NEW ANTIBODY THAT RECOGNIZES A CONFORMATIONAL VARIANT OF P53 SPECIFIC FOR ALZHEIMER’S AT THE PRE-CLINICAL AND PRODROMAL STAGES OF THE DISEASE (2019) (0)
- Comparison of the prevalence of neuropsychiatric behaviors between amnestic and nonamnestic MCI subjects (2012) (0)
- P4.028 Functional and behavioral effects of memantinein Alzheimer's disease (2004) (0)
- Behavioral disturbances in early familial Alzheimer's disease (2009) (0)
- Alzheimer's disease. (2004) (0)
- Contents (2019) (0)
- IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER’S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS (2018) (0)
- 3D mapping of associations between Amyloid-PET and CSF biomarkers and hippocampal morphology in normal aging and Alzheimer's disease (2009) (0)
- MRI CLASSIFIERS CHARACTERIZE MILD TRAUMATIC BRAIN INJURY IN SYMPTOMATIC AND PRESYMPTOMATIC STAGES AND DIFFERENTIATE FROM ALZHEIMER’S DISEASE–RELATED IMPAIRMENT (2018) (0)
- SPECT and dementia (1992) (0)
- EFFECTS OF RISPERIDONE AND GALANTAMINE TREATMENT ON ALZHEIMER BIOMARKER LEVELS IN CEREBROSPINAL FLUID (2017) (0)
- SUBCORTICAL HYPERINTENSITIES IN ALZHEIMER's DISEASE: ASSOCIATED CLINICAL AND CORTICAL METABOLIC FINDINGS (1999) (0)
- 102 - IPA Guidelines on Dementia and Agitation: From Provisional to Final (2021) (0)
- Frontotemporal Dementia and Related Syndromes (2010) (0)
- P2-358 Cognitive processing speed and myelin breakdown in older individuals (2006) (0)
- Nortiptyline versus fluoxetine in the treatment of depression and in shortterm recovery after stroke: a placebo-controlled, double-blind study (2000) (0)
- Behavioral Neurology, ed 3 (1986) (0)
- DO NEUROLOGISTS HAVE A FUTURE IN NEUROIMAGING?. AUTHORS' REPLY (1998) (0)
- Neuropsychiatric Inventory--Questionnaire Version (2014) (0)
- DONEPEZIL FOR NURSING HOME PATIENTS WITH DEMENTIA: A REINTERPRETATION OF THE EVIDENCE ‐ Response to the Editor (2003) (0)
- Anti-dementia drugs: What difference do they make? (1998) (0)
- Chapter 16 Behavioral Syndromes and Their Treatment (2007) (0)
- P1-456 The effect of memantine on distinct behavior syndromes in moderate to severe AD patients (2006) (0)
- Comprar Progress in Neurotherapeutics and Neuropsychopharmacology | Jeffrey L. Cummings | 9780521115612 | Cambridge University Press (2007) (0)
- Workshop reports from the third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines. (2006) (0)
- BACE INHIBITOR VERUBECESTAT (MK-8931): BASELINE CHARACTERISTICS FOR PARTICIPANTS ENROLLED IN THE PHASE II/III EPOCH ALZHEIMER’S DISEASE TRIAL (2016) (0)
- Clinical and quantitative fluorodeoxyglucose positron emission tomography in presymptomatic and symptomatic persons inheriting familial Alzheimer's disease mutations (2010) (0)
- Drugs and aging: Foreword (2005) (0)
- Sex-dependent Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment (2021) (0)
- Imaging and behavior in Parkinson’s disease: structural imaging (2013) (0)
- Drugs and aging: Foreword (2005) (0)
- Dementia with Lewy Bodies: Consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) (1996) (0)
- Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study (2019) (0)
- Course and prognostic significance of performance in reading, spelling and oral language in Alzheimer's disease (1996) (0)
- P2-164 Biochemical markers in blood and cerebrospinal fluid of persons with or at-risk for familial AD (2006) (0)
- Session 2 , Monday 10 September Ageing and dementia 2 P 2001 High-dose 13 . 3 mg / 24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living : analysis of autonomy and higher-level function subscales (2012) (0)
- A Cry for Help: Treating Involuntary Emotional Expression Disorder; Pharmacotherapy Can Lessen the Impact of Uncontrollable Laughing or Crying (2008) (0)
- Memantine With Cholinesterase Inhibitors Maintains Improvements of Psychiatric Symptoms vs Cholinesterase Inhibitors Alone: Post Hoc Analyses From 3 Randomized, Double-blind, Placebo-controlled Studies in Patients With Alzheimer’s Disease (P6.177) (2018) (0)
- IN54-TH-03 Disease-modifying drugs and vaccines for Alzheimer's disease (2009) (0)
- Executive dysfunction in Alzheimer's disease: Implications for future practice (2005) (0)
- CLOZAPINE IN THE MANAGEMENT OF PSYCHOSIS IN PATIENTS WITH PARKINSON??S DISEASE: (1999) (0)
- P1-217: Automated 3D mapping of caudate atrophy and ventricular enlargement in Parkinson's disease with and without dementia (2008) (0)
- Dementia and Parkinsonism - An Emerging Research Area (1995) (0)
- Management of neuropsychiatric aspects of dementia (2003) (0)
- Neurobiological Bases of Cognition, Emotion, and Behavior (2018) (0)
- Dextromethorphan/quinidine (AVP-923) phase 2 study for treatment of agitation in Alzheimer’s disease: Comparing the enrolled agitation sample with the international psychogeriatric association definition of agitation in cognitive disorders (NCT01584440) (2015) (0)
- Title Alzheimer ' s disease progression by geographical region in a clinical trial setting Permalink (2015) (0)
- Dementia with Lewy Bodies: Index (1996) (0)
- Book Review Dementia and Aging: Ethics, Values, and Policy Choices Edited by Robert H. Binstock, Stephen G. Post, and Peter J. Whitehouse. 184 pp. Baltimore, Johns Hopkins University Press, 1992. $18.95. 0-8018-4545-9 (1993) (0)
- A-17Sex Differences in Hippocampal Subfield Volume: The Impact of Amyloid Burden (2017) (0)
- Effects of simufilam on cerebrospinal fluid biomarkers in Alzheimer’s disease: A randomized clinical trial (2021) (0)
- Clinical Trials in Neurology: Preface (2012) (0)
- The impact of low dementia research funding on brain health for decision makers: A reflection on current health statistics (2023) (0)
- Geriatric Neuropsychopharmacology: Unmet Needs (2001) (0)
- Effects of Donepezil on Behavior in Severe AD Patients With Multi-Domain Responses (2008) (0)
- Distinguishing dementias. (1986) (0)
- Dementia: P. Whitehouse (Ed.) (Davis, Philadelphia, PA, 1993, 465 p., Price: US $90.00) (1994) (0)
- Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume (2017) (0)
- Donepezil for nursing home patients with dementia: A reinterpretation of the evidence [1] (multiple letters) (2003) (0)
- Disease Mechanisms in Neuroscience (2007) (0)
- Time and the Nervous System (1991) (0)
- Subject Index Vol. 10, 1999 (1999) (0)
- Consensus provisional definition of agitation in cognitive disorders (2019) (0)
- Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials (2016) (0)
- Alterations in sexual behavior following focal brain injury (2000) (0)
- Dextromethorphan/quinidine (AVP-923) for treatment of agitation in patients with Alzheimer’s disease: Analysis of week 10 results for patients treated only with AVP-923 versus patients receiving only placebo (NCT01584440) (2015) (0)
- Dr. Cummings and Associates Reply (1989) (0)
- Gene expression correlates of hippocampal atrophy across in cognitively normal elderly and MCI (2010) (0)
- Neurobiology of neuropsychiatric symptoms in dementias (2003) (0)
- P2-389 EMPLOYING LYMPHOCYTE PROLIFERATIONAS A MEANS TO ASSESS CELL CYCLE DYSREGULATION IN COGNITIVELY IMPAIRED SUBJECTS: CLINICAL PERFORMANCE OF THE LYMPRO ASSAY (2014) (0)
- The foundation and architecture of precision medicine in neurology and psychiatry (2023) (0)
- Treatment of Psychosis in Parkinson's disease and Parkinson's disease dementia (2014) (0)
- Clinical and Quantitative Fluorodeoxyglucose Positron Emission Tomography in Pre- and Symptomatic Persons Inheriting Familial Alzheimer's Disease Mutations (2010) (0)
- Advances in the Neuropsychopharmacologic Management of Behavioral Alterations in Alzheimer’s Disease (2003) (0)
- Reply from the Authors (1996) (0)
- Attention and working memory in familial Alzheimer's disease (2010) (0)
- Contents Vol. 46 (2019) (0)
- Efficacy and safety of AXS‐05, a novel oral NMDA receptor antagonist with multimodal activity in agitation associated with Alzheimer’s disease: Results from ADVANCE‐1 — A phase 2/3, double‐blind, active and placebo‐controlled trial (2020) (0)
- Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies (2010) (0)
- CNS volume 18 issue 3 Cover and Front matter (2013) (0)
- EFFECTS OF THE EPIGENETIC BET-INHIBITOR SMALL MOLECULE APABETALONE ON COGNITION IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE (2019) (0)
- Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. (2008) (0)
- Behavioral responses to cholinesterase inhibitors (2000) (0)
- CLINICAL: CHOLINERGIC THERAPEUTICS O4-03-01 MAINTENANCE OF COGNITIVE IMPROVEMENT TREATMENT RESPONSE WITH MEMANTINE AND DONEPEZIL: POST HOC ANALYSES FROM A PLACEBO- CONTROLLED STUDY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE (2017) (0)
- Dr. Altshuler and Associates Reply (1987) (0)
- Increased fMRI Activity with Age in Left Temporal Lobe of Familial Alzheimer's Disease Mutation Carriers (2010) (0)
- Reaching a Diagnosis of a Dementia Subtype (2008) (0)
- Neurobehavioral Rating Scale (NRS) 1992 (2004) (0)
- Neuropsychiatry in the Elderly (2001) (0)
- Alzheimer's Disease: Unskilled Vulgarity Decays Into Stunning Artistic Genius-Reply (1988) (0)
- 689 First clinical symptoms of frontotemporal dementia (1998) (0)
- IDALOPIRDINE, A 5-HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’S DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM (2017) (0)
- Key developmental milestones for tau therapeutics (2020) (0)
- A - 26Awareness of Psychiatric Symptoms and Caregiver Distress Among Older Adults in a Memory Disorders Clinic (2018) (0)
- P1-282: Decreased activation in the left medial parietal lobe in presymptomatic familial Alzheimer's disease mutation carriers in FMRI during an unrelated word pair memory task (2008) (0)
- P1-140 SOLUBLE BACE ACTIVITYAND SAPPb LEVELS DO NOT DIFFERENTIATE ALZHEIMER’S DISEASE AND AGE-MATCHED CONTROL CEREBROSPINAL FLUID IN THEADNI-1 COHORT (2013) (0)
- Books Received (2001) (0)
- SELEGILINE AND AKATHISIA, TARDIVE DYSKINESIA, AND NEGATIVE SCHIZOPHRENIC SYMPTOMS (1992) (0)
- Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jeffrey L. Cummings.?
Jeffrey L. Cummings. is affiliated with the following schools:
